To explore the potential reasons why CCS/CRF patients benefit more from ICIs therapy, we performed IHC for CRC tumors undergoing radical resection and showed that CD8+ T cells were more frequently infiltrating in patients with CCS/CRF than in patients without CCS/CRF. Here, CD8A is linked to colorectal carcinoma.